Have questions on 340B? Timothy Paine can answer your questions.

Date Posted: 06.08.2022
Timothy Paine, Principal Consultant

As the Public Health Service (PHS) 340B program passes the 30-year mark, seminal events in the program’s history have shaped the landscape we see today. Far from being a bureaucratic regulation that all parties sleepily adopt, the 340B program has become a hot button for all those involved as well as those seeking to impact it from beyond the typical Covered Entity, Manufacturer and Government participants. With so many dollars at stake, attention – and tension – is riding high on actions by the existing stakeholders that have made a significant impact on the program in ways that were unimaginable a few short years ago. Where will the 340B program be 10 years from now? Will it survive as we know it?

The recent changes in the 340B program have a decided impact on and implications for patients, prescribers, payers, pharmacies, and the physical channel or flow of medications. We will explore each of those parties and end with specific calls to action for stakeholders in this critical program.

Contact Cynthia Keveney at Blue Fin Group for additional information. [email protected]


Click here to watch his video:

About the Author Timothy Paine

With more than three decades of experience in the life sciences industry, Tim Paine has significant experience taking pharmaceutical and biotech products to market. His experience spans commercial development from clinical trial through loss of exclusivity. Tim has worked across a wide range of therapeutic areas and is deeply familiar with cell and gene therapies, orphan rare diseases and an array of specialty areas. His experience includes establishing strategy to operational execution. With his diverse scientific background across sites of care from retail to clinic to health systems, Tim brings a breadth of perspectives to all client engagements and always focuses on the best possible outcome for the patient. Prior to joining Blue Fin Group, Tim held the role of Vice President, Pharmaceutical Strategy and Relations for Fairview Pharmacy Services, part of the M Health Fairview Health System in Minneapolis, MN. With Fairview’s nation-leading position in health system specialty pharmacy, Tim has been a leader in helping shape pharma’s view of working with health system specialty pharmacies and advancing the partnership perspective towards mutual advancement of the Triple Aim. Tim’s educational background in microbiology combined with years in product and business development, uniquely positions him to develop solutions that maximize a product’s potential for manufacturers, patients and providers.